GlobalData, a data and analytics company, on Friday said that tirzepatide is the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for obesity treatment in China is expected to enhance its market positioning in China.
According to the analytics company, Eli Lilly’s tirzepatide (Mounjaro) has recently been approved by the National Medical Products Administration (NMPA) for treating obesity. This approval is based on the positive results from the SURMOUNT-CN clinical trial.